AbbVie Inc. filed a preliminary prospectus supplement (Form 424B5) on August 4, 2026, disclosing a multi-tranche senior note offering consisting of one floating rate series and eight fixed rate series, with proceeds intended primarily to fund the acquisition of Apogee Therapeutics, Inc.

Key Highlights

  • Nine tranches offered: AbbVie is offering one series of Senior Floating Rate Notes and eight series of Senior Fixed Rate Notes, each with maturities and coupon rates left blank in this preliminary filing.
  • Acquisition-linked use of proceeds: The company disclosed that net proceeds will be used primarily to fund a portion of its cash payment obligations in connection with the acquisition of Apogee Therapeutics, Inc., plus related fees and expenses.
  • Special Mandatory Redemption at 101%: If the Acquisition Agreement is terminated or AbbVie notifies the Trustee it will not pursue the Specified Acquisition, AbbVie must redeem the designated Mandatorily Redeemable Notes at 101% of principal plus accrued and unpaid interest.
  • Long-Term Notes exempt from mandatory redemption: Two series designated as the Long-Term Notes will not be subject to any Special Mandatory Redemption.
  • Unsecured and unsubordinated: The Notes will rank equally in right of payment with all of AbbVie's existing and future unsecured, unsubordinated indebtedness.
  • Minimum denomination of $2,000: Notes will be issued in minimum denominations of $2,000 and in integral multiples of $1,000 in excess thereof.
  • Joint book-runners: Morgan Stanley, BofA Securities, J.P. Morgan, and Societe Generale are named as joint book-running managers.

AbbVie's Preliminary Multi-Series Note Offering and Apogee Acquisition Financing

According to the filing, AbbVie Inc. (NYSE: ABBV), a Delaware corporation, is offering nine series of senior notes under a shelf registration statement on Form S-3 that became effective upon filing on February 14, 2025. The preliminary prospectus supplement, dated August 4, 2026, does not yet disclose the principal amounts, coupon rates, or maturity years for any of the nine series, as those fields remain blank in the preliminary document. The notes will not be listed on any securities exchange, and the filing states that "currently there is no public market for any series of the Notes."

The filing discloses that the primary intended use of net proceeds is to fund a portion of AbbVie's cash payment obligations in connection with its acquisition of Apogee Therapeutics, Inc., along with fees, expenses, and other amounts related to that transaction. Any remaining proceeds may be used for general corporate purposes, which the filing states "may include the repayment or repurchase of outstanding debt." The filing notes that "this offering is not conditioned upon the consummation of the Specified Acquisition."

The Special Mandatory Redemption provision applies to the Mandatorily Redeemable Notes only. If AbbVie publicly announces termination of the Acquisition Agreement or notifies the Trustee in writing that it will not pursue the acquisition, it must redeem those notes at 101% of principal plus accrued and unpaid interest. The filing specifies that there is no escrow account or security interest in the offering proceeds for the benefit of noteholders. The filing also contains forward-looking statements, which it identifies as the company's own and subject to its cautionary language beginning on page S-53 of the prospectus supplement.

What Was Disclosed

AbbVie filed a preliminary 424B5 prospectus supplement on August 4, 2026, disclosing a nine-tranche senior note offering linked to the planned acquisition of Apogee Therapeutics, with specific amounts, rates, and maturities to be determined at pricing.